Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home Item
A Nicotine-Focused Regulatory Strategy: The Science , homeMarch 13, 2026, 11:00 a.m. | Dorothy Hatsukami, Ph.D., Professor of Psychiatry and Behavioral Sciences and Forster Family Chair in Cancer Prevention, Masonic Cancer Center, University of Minnesota | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
From BDNF to Rett Syndrome: Synapses, Networks, and Social Behaviors in Mecp2 Mutant Mice , homeMarch 27, 2026, 11:00 a.m. | Lucas Pozzo-Miller, Ph.D., Mall Family Endowed Professor for Genetic Autism Research, Department of Pediatrics & Human Development, College of Medicine, Michigan State University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home Item
The Effects of Aging and Physical Activity on Cardiovascular Structure and Function , homeApril 10, 2026, 11:00 a.m. | Ben Levine, M.D., Professor of Medicine and Cardiology, Clinical Heart and Vascular Center, Distinguished Professorship in Exercise Sciences, UT Southwestern Medical Center | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home Item
The Golden Age of Immunology Research , homeApril 16, 2026, 5:30 p.m. (Reception at 5 p.m.) | Lewis Lanier, Ph.D., J. Michael Bishop Distinguished Professor and Chair Emeritus, Department of Microbiology and Immunology, University of California, San Francisco; Elected Member, National Academy of Sciences | Maury Strauss Distinguished Public Lecture
-
Home Item
New Insights into Cardiac Mechanobiology: Role of Caveolar Nanodomains in Mechano-electrochemical Signal Transduction , homeApril 17, 2026, 11:00 a.m. | Alexey Glukhov, Ph.D., Associate Professor of Cardiovascular Medicine, UW-Madison Wisconsin Institutes for Medical Research, University of Wisconsin | Co-Sponsored by the Center for Vascular and Heart Research, Fralin Biomedical Research Institute
-
Home Item
Advancing the Treatment of Traumatic Stress and Addictions: How Data Science Can Move the Field Forward , homeMay 1, 2026, 11:00 a.m. | Denise Hien, Ph.D., Helen E. Chaney Endowed Chair in Alcohol Studies, Distinguished Professor, Rutgers Center of Alcohol & Substance Use Studies, Graduate School of Applied and Professional Psychology, Rutgers University-New Brunswick | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center